These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. Woodland A; Grimaldi R; Luksch T; Cleghorn LA; Ojo KK; Van Voorhis WC; Brenk R; Frearson JA; Gilbert IH; Wyatt PG ChemMedChem; 2013 Jul; 8(7):1127-37. PubMed ID: 23776181 [TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates. Yang G; Zhu W; Kim K; Byun SY; Choi G; Wang K; Cha JS; Cho HS; Oldfield E; No JH Antimicrob Agents Chemother; 2015 Dec; 59(12):7530-9. PubMed ID: 26392508 [TBL] [Abstract][Full Text] [Related]
6. Casein kinase 1 isoform 2 is essential for bloodstream form Trypanosoma brucei. Urbaniak MD Mol Biochem Parasitol; 2009 Aug; 166(2):183-5. PubMed ID: 19450734 [TBL] [Abstract][Full Text] [Related]
11. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Valenciano AL; Ramsey AC; Santos WL; Mackey ZB Bioorg Med Chem; 2016 Oct; 24(19):4647-4651. PubMed ID: 27519462 [TBL] [Abstract][Full Text] [Related]
12. A novel protein kinase is essential in bloodstream Trypanosoma brucei. Jensen BC; Booster N; Vidadala RS; Maly DJ; Parsons M Int J Parasitol; 2016 Jul; 46(8):479-83. PubMed ID: 27018127 [TBL] [Abstract][Full Text] [Related]
13. Validation of spermidine synthase as a drug target in African trypanosomes. Taylor MC; Kaur H; Blessington B; Kelly JM; Wilkinson SR Biochem J; 2008 Jan; 409(2):563-9. PubMed ID: 17916066 [TBL] [Abstract][Full Text] [Related]
14. Trypanosoma brucei: Inhibition of cathepsin L is sufficient to kill bloodstream forms. Steverding D; Rushworth SA; Florea BI; Overkleeft HS Mol Biochem Parasitol; 2020 Jan; 235():111246. PubMed ID: 31743688 [TBL] [Abstract][Full Text] [Related]
15. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164 [TBL] [Abstract][Full Text] [Related]
16. The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis. Urich R; Grimaldi R; Luksch T; Frearson JA; Brenk R; Wyatt PG J Med Chem; 2014 Sep; 57(18):7536-49. PubMed ID: 25198388 [TBL] [Abstract][Full Text] [Related]
17. A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β. Swinney ZT; Haubrich BA; Xia S; Ramesha C; Gomez SR; Guyett P; Mensa-Wilmot K; Swinney DC PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004506. PubMed ID: 26942720 [TBL] [Abstract][Full Text] [Related]
18. Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent. Yang PY; Wang M; Liu K; Ngai MH; Sheriff O; Lear MJ; Sze SK; He CY; Yao SQ Chemistry; 2012 Jul; 18(27):8403-13. PubMed ID: 22674877 [TBL] [Abstract][Full Text] [Related]
19. Orally Active and Selective Tubulin Inhibitors as Anti-Trypanosome Agents. Nanavaty V; Lama R; Sandhu R; Zhong B; Kulman D; Bobba V; Zhao A; Li B; Su B PLoS One; 2016; 11(1):e0146289. PubMed ID: 26771307 [TBL] [Abstract][Full Text] [Related]
20. Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. Oduor RO; Ojo KK; Williams GP; Bertelli F; Mills J; Maes L; Pryde DC; Parkinson T; Van Voorhis WC; Holler TP PLoS Negl Trop Dis; 2011 Apr; 5(4):e1017. PubMed ID: 21483717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]